- Home
- ADPT vs BBAI Comparison
ADPT vs BBAI Comparison
Compare ADPT & BBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- BBAI
- Stock Information
- Founded
- ADPT 2009
- BBAI 2020
- Country
- ADPT United States
- BBAI United States
- Employees
- ADPT N/A
- BBAI N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- BBAI EDP Services
- Sector
- ADPT Health Care
- BBAI Technology
- Exchange
- ADPT Nasdaq
- BBAI Nasdaq
- Market Cap
- ADPT 1.1B
- BBAI 1.0B
- IPO Year
- ADPT 2019
- BBAI N/A
- Fundamental
- Price
- ADPT $9.03
- BBAI $3.15
- Analyst Decision
- ADPT Buy
- BBAI Strong Buy
- Analyst Count
- ADPT 6
- BBAI 3
- Target Price
- ADPT $9.83
- BBAI $5.17
- AVG Volume (30 Days)
- ADPT 3.0M
- BBAI 56.5M
- Earning Date
- ADPT 05-01-2025
- BBAI 05-01-2025
- Dividend Yield
- ADPT N/A
- BBAI N/A
- EPS Growth
- ADPT N/A
- BBAI N/A
- EPS
- ADPT N/A
- BBAI N/A
- Revenue
- ADPT $189,527,000.00
- BBAI $159,872,000.00
- Revenue This Year
- ADPT $21.20
- BBAI $9.65
- Revenue Next Year
- ADPT $21.99
- BBAI $12.82
- P/E Ratio
- ADPT N/A
- BBAI N/A
- Revenue Growth
- ADPT 8.61
- BBAI 9.40
- 52 Week Low
- ADPT $2.99
- BBAI $1.17
- 52 Week High
- ADPT $10.28
- BBAI $10.36
- Technical
- Relative Strength Index (RSI)
- ADPT 57.82
- BBAI 49.01
- Support Level
- ADPT $8.38
- BBAI $2.96
- Resistance Level
- ADPT $9.51
- BBAI $3.58
- Average True Range (ATR)
- ADPT 0.66
- BBAI 0.27
- MACD
- ADPT 0.16
- BBAI 0.05
- Stochastic Oscillator
- ADPT 63.02
- BBAI 52.57
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment. Company generate revenue by providing customers with Edge AI-powered decision intelligence solutions and services for data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics and predictive visualization. It generate revenue from providing both software and services to customers.